Founded in 2025, Lila Sciences operates in biotechnology / ai. The latest valuation stands at $8.5B (pre-money). No public ticker exists for the company.
1 valuation. The latest, $8.5B pre-money, was set by the Series B in Jun 2026.
Alumni VenturesLila Sciences is building what it calls Scientific Superintelligence: an AI model paired with proprietary AI Science Factory instruments that generate hypotheses, design and run experiments, and learn from new data in real time, aiming to execute the entire scientific method autonomously across medicine, materials, energy and defense. Its autonomous science platform has already discovered an ultra-stable mRNA, which it says outperformed a leading CAR-T therapy in non-human primates.
Flagship Pioneering unveiled Lila Sciences in March 2025 after two years in stealth, and the company is headquartered in the United States, led by CEO Geoff von Maltzahn.
Listed funds carry late-stage private names. A fund's latest schedule of investments shows whether it holds Lila Sciences.
Often trade at a premium or discount to NAV.
Platforms match existing holders with buyers. Lila Sciences availability at any moment is set by the holders.
High minimums, transfer approval, company right-of-first-refusal.
Valuations, rounds and IPO status for every company in the directory — Lila Sciences included.
The routes section explains what is realistically available for a company at this stage.
No. Lila Sciences is a private company; its shares do not trade on a public exchange.
The closest biotechnology / ai peers are on the competitors page.
Perpetual markets for stocks, gold, indices and pre-IPO names — settled on-chain, no wallet-to-exchange transfers.
